Cell and Gene Outsourcing

  1. Sustainable Approaches To Oligonucleotide Manufacturing

    An industry expert shares about sustainable Oligo manufacturing approaches that can save time, cost, and resources – while improving purity, quality, and scalability of these promising therapeutics.

  2. How To Apply Quality By Design Principles To Cell And Gene Therapy Release Testing 3/21/2024

    Review how to develop and use QC assays that can facilitate both product and process understanding and control.

  3. Delivering Therapies To Patients At Scale And At Speed 10/13/2021

    Resilience is addressing a defining challenge: Biopharmaceutical manufacturing has not kept pace with scientific advancement, preventing new discoveries from reaching patients at speed or scale.

  4. Advancing Viral Vector Manufacturing: The Importance Of The Cell Line 9/16/2024

    Explore the pivotal role of cell lines in viral vector manufacturing, a complex, multi-step process that has traditionally been both time-consuming and labor-intensive.

  5. Optimizing Viability And Standardization For Clinical Excellence 10/2/2024

    Explore how IntegriCell™ delivers high-quality, manufacture-ready cryopreserved leukopaks, vital for consistent and reliable cell therapy production.

  6. Secure And Industrialize Your CGT Process Towards cGMP Manufacturing

    Learn the principles of commercialization readiness and guidance to address them in process development as well as the best time to implement automation and minimize commercialization risks.

  7. Meeting Needs And Exceeding Expectations Worldwide 10/16/2024

    Whether you are looking to optimize your existing formulations or require full-scale manufacturing solutions, Boehringer Ingelheim BioXcellence™ is dedicated to helping you realize your vision and deliver impactful therapies.

  8. Preparing For FDA Pre-Approval Inspection: Quality And Regulatory Topics

    Consider these strategies for meeting quality and regulatory requirements in cell and gene therapies that can also help to identify issues early, reduce risks, and prevent delays and rework.

  9. Early Preclinical Development: A Successful Transition To cGMP Manufacturing 12/2/2024

    Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

  10. Pioneering Solutions That Turn Hope Into Reality

    The number of AAV-mediated therapies in clinical trials continues to rise, increasing demand for doses. A scalable platform is crucial to ensure a seamless transfer from pre-clinical to commercial.